Recently patented and promising ORL-1 ligands: Where have we been and where are we going?

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 3, 2010, Pages 291-305

  Largent Milnes, Tally M ^a   Vanderah, Todd W ^b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Multi target approach; Nociceptin receptor; Nociceptin opioid receptor like receptor; Orphanin FQ; Pain

Indexed keywords

1 (1 CYCLOOCTYLMETHYL 3 HYDROXYMETHYL 4 PIPERIDYL) 3 ETHYL 1,3 DIHYDRO 2H BENZIMIDAZOL 2 ONE; 1 [ 1 (CYCLOOCTYLMETHYL) 1,2,3,6 TETRAHYDRO 5 (HYDROXYMETHYL) 4 PYRIDINYL] 3 ETHYL 1,3 DIHYDRO 2H BENZIMIDAZOL 2 ONE; 1 BENZYL N [ 3 [SPIROISOBENZOFURAN 1 (3H),4' PIPERIDIN 1 YL]PROPYL]PYRROLIDINE 2 CARBOXAMIDE; 1 METHYL 7 [[ 4 ( 2,6 DICHLOROPHENYL)PIPERIDIN 1 YL]METHYL] 6,7,8,9 TETRAHYDRI 5H BENZOCYCLOHEPTEN 5 OL; 4 [ 3 [( 2 ) 2,3 DIHYDROXYPROPYL] 2 OXO 2,3 DIHYDRO 1H BENZIMIDAZOL 1 YL] 1 ( 1,3,4 )SPIRO[BICYCLO[ 2.2.1]HEPTANE 2,1' CYCLOPROPAN] 3YLMETHY]PIPERIDINE; 7 [4 (2,6 DICHLOROPHENYL) 1 PIPERIDINYLMETHYL] 6,7,8,9 TETRAHYDRO 1 METHYL 5H BENZOCYCLOHEPTEN 5 OL; 8 (2,3,3A,4,5,6 HEXAHYDRO 1H PHENALEN 1 YL) 1 PHENYL 1,3,8 TRIAZASPIRO[4.5]DECAN 4 ONE; 8 ECENAPHTHEN 1 YL 1 PHENYL 1,3,8 TRIAZA SPIRO[ 4,5 ]DECAN 4 ONE; ACENAPHTHENE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; BUPRENORPHINE; CYCLOOXYGENASE 2 INHIBITOR; LIGAND; N (4 AMINO 2 METHYL 6 QUINOLINYL) 2 (4 ETHYLPHENOXYMETHYL)BENZAMIDE; NOCICEPTIN; NOCICEPTIN OPIOID PEPTIDE; NOCICEPTIN RECEPTOR; NOCICEPTIN RECEPTOR AGONIST; NOCICEPTIN RECEPTOR ANTAGONIST; OPIATE RECEPTOR; OPIOID RECEPTOR LIKE RECEPTOR 1; PIPERIDINE DERIVATIVE; RECEPTOR; RO 656570; SR 14150; SR 16435; TRAP 101; UFP 101; UFP 112; UNCLASSIFIED DRUG; UNINDEXED DRUG; US 2006030565; US 6410561 B1; US 7094784; US 7485650; WO 2006087340;

ALLODYNIA; ANXIETY DISORDER; BINDING AFFINITY; CHRONIC PAIN; CLINICAL TRIAL; COUGHING; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; HOST; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NOCICEPTION; NONHUMAN; PAIN; PATENT; PRIMATE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SPINAL ANESTHESIA; STRUCTURE ACTIVITY RELATION; TREATMENT INDICATION;

ANALGESICS; ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; LIGANDS; PAIN; PATENTS AS TOPIC; RECEPTORS, OPIOID;

EID: 77649124285     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543771003602004     Document Type: Review

References (140)

1. Mollereau C, Parmentier M, Mailleux P, et al. ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett 1994;341(1):33-38
2. Civelli O. The orphanin FQ/nociceptin (OFQ/N) system. Results Probl Cell Differ 2008;46:1-25
3. Mogil JS, Pasternak GW. The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. Pharmacol Rev 2001;53(3):381-415
4. Meunier JC. Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor. Eur J Pharmacol 1997;340(1):1-15
5. Meunier JC, Mollereau C, Toll L, et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 1995;377(6549):532-535
6. Reinscheid RK, Nothacker HP, Bourson A, et al. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science 1995;270(5237):792-794
7. Foord SM, Bonner TI, Neubig RR, et al. International Union of Pharmacology. XLVI. G protein-coupled receptor list. Pharmacol Rev 2005;57:279-288
8. New DC, Wong YH. The ORL1 receptor: molecular pharmacology and signaling mechanisms. Neurosignals 2002;11(4):197-212
9. Butour JL, Moisand C, Mazarguil H, et al. Recognition and activation of the opioid receptor-like ORL 1 receptor by nociceptin, nociceptin analogs and opioids. Eur J Pharmacol 1997;321(1):97-103
10. Chan JS, Yung LY, Lee JW, et al. Pertussis toxin-insensitive signaling of the ORL1 receptor: coupling to Gz and G16 proteins. J Neurochem 1998;71(5):2203-2210
11. Matthes H, Seward EP, Kieffer B, et al. Functional selectivity of orphanin FQ for its receptor coexpressed with potassium channel subunit in Xenopus laevis oocytes. Mol Pharmacol 1996;50:447-450
12. Ikeda K, Kobayashi K, Kobayashi T, et al. Functional coupling of the nociceptin/orphanin FQ receptor with the G protein-activated K+ (GIRK) channel. Mol Brain Res 1997;45:117-126
13. Vaughan CW, Christie MJ. Increase by the ORL1 receptor (opioid receptor-like 1) ligand, nociceptin, of inwardly rectifying K conductance in dorsal raphe nucleus neurons. Br J Pharmacol 1996;117:1609-1611
14. Fukuda K, Shoda T, Morikawa H, et al. Activation of mitogen-activated protein kinase by the nociceptin receptor expressed in Chinese hamster ovary cells. FEBS Lett 1997;412(2):290-294
15. Neal CR Jr, Mansour A, Reinscheid R, et al. Localization of orphanin FQ (nociceptin) peptide and messenger RNA in the central nervous system of the rat. J Comp Neurol 1999;406(4):503-547
16. Neal CR Jr, Mansour A, Reinscheid R, et al. Opioid receptor-like (ORL1) receptor distribution in the rat central nervous system: comparison of ORL1 receptor mRNA expression with (125) I-[(14)Tyr]-orphanin FQ binding. J Comp Neurol 1999;412(4):563-605
17. Mollereau C, Simons MJ, Soularue P, et al. Structure, tissue distribution, and chromosomal localization of the prepronociceptin gene. Proc Natl Acad Sci USA 1996;93(16):8666-8670
18. Nothacker HP, Reinscheid RK, Mansour A, et al. Primary structure and tissue distribution of the orphanin FQ precursor. Proc Natl Acad Sci USA 1996; 93(16):8677-8682
19. Wang JB, Johnson PS, Imai Y, et al. cDNA cloning of an orphan opiate receptor gene family member and its splice variant. FEBS Lett 1994;348:75-79
20. Available from: www.patentstorm.com
21. Calo' G, Bigoni R, Rizzi A, et al. Nociceptin/orphanin FQ receptor ligands. Peptides 2000;21(7):935-947
22. Bojnik E, Farkas J, Magyar A, et al. Selective and high affinity labeling of neuronal and recombinant nociceptin receptors with the hexapeptide radioprobe [(3)H]Ac-RYYRIK-ol. Neurochem Int 2009;55(7):458-466
23. Calo' G, Guerrini R, Rizzi A, et al. Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br J Pharmacol 2000; 129(7):1261-1283
24. Calo G, Rizzi A, Bogoni G, et al. The mouse vas deferens: a pharmacological preparation sensitive to nociceptin. Eur J Pharmacol 1996;311(1):R3-5
25. Okada K, SUjaku T, Chuman Y, et al. Highly potent nociceptin analog containing the Arg-Lys triple repeat. Biochem Biophys Res Commun 2000;278(2):493-498
26. Rizzi A, Spagnolo B, Wainford RD, et al. In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor. Peptides 2007;28(6):1240-1251
27. Guerrini R, Salvadori S, Calo G, et al. Highly potent full and partial agonists and antagonists of the nociception/orphanin FQ receptor. WO2006087340A2; 2006
28. Berger H, Bigoni R, Albrecht E, et al. The nociceptin/orphanin FQ receptor ligand acetyl-YYRIK-amide exhibits antagonistic and agonistic properties. Peptides 2000;21(7):1131-1139
29. Dooley CT, Spaeth CG, Berzetei-Gurske IP, et al. Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1. J Pharmacol Exp Ther 1997;283(2):735-741
30. Barlocco D, Cignarella G, Giardina GA, et al. The opioid-receptor-like 1 (ORL-1) as a potential target for new analgesics. Eur J Med Chem 2000;35(3):275-282
31. Guerrini R, Calo G, Rizzi A, et al. A new selective antagonist for the nociception receptor. Brit J Pharmacol 1998;123:163-165
32. Guerrini R, Calo G, Rizzi A, et al. Address and message sequences for the nociception receptor: a structure-activity study of nociception-(1-13)-peptide amide. J Med Chem 1997;40:1789-1793
33. Salvadori S, Guerrini R, Calo G, et al. Structure-activity studies on nociceptin/orphanin FQ: from full agonist, to partial agonist, to pure antagonist. Farmaco 1999;54(11-12):810-825
34. Hashimoto Y, Calö G, Guerrini R, et al. Antagonistic effects of [Nphe1] nociceptin(1-13)NH2 on nociceptin receptor mediated inhibition of cAMP formation in Chinese hamster ovary cells stably expressing the recombinant human nociceptin receptor. Neurosci Lett 2000;278(1-2):109-112
35. Calo G, Rizzi A, Rizzi D, et al. [Nphe1, Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br J Pharmacol 2002;136(2):303-311
36. Fioravanti B, Vanderah TW. The ORL-1 receptor system: are there opportunities for antagonists in pain therapy? Curr Top Med Chem 2008;8(16):1442-1451
37. Chang M, Peng YL, Dong SL, et al. Structure-activity studies on different modifications of nociceptin/orphanin FQ: identification of highly potent agonists and antagonists of its receptor. Regul Pept 2005; 130(3):116-122
38. Peng YL, Chang M, Dong SL, et al. Novel potent agonist [(pF)Phe4,Aib7, Aib11,Arg14,Lys15]N/OFQ-NH2 and antagonist [Nphe1,(pF)Phe4,Aib7,Aib11, Arg14,Lys15]N/OFQ-NH2 of nociceptin/orphanin FQ receptor. Regul Pept 2006;134(2-3):75-81
39. Rover S, Adam G, Cesura AM, et al. High-affinity, non-peptide agonists for the ORL1 (orphanin FQ/nociceptin) receptor. J Med Chem 2000;43(7):1329-1338 (Pubitemid 30212574)
40. Jenck F, Wichmann J, Dautzenberg FM, et al. A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1:anxiolytic profile in the rat. Proc Natl Acad Sci USA 2000;97(9):4938-4943
41. Wichmann J, Adam G, Rover S, et al. Synthesis of (1S,3aS)-8-(2,3,3a,4,5, 6-hexahydro-1H-phenalen-1-yl)-1-phenyl- 1,3,8-triaza-spiro[4. 5]decan-4-one, a potent and selective orphanin FQ (OFQ) receptor agonist with anxiolyticlike properties. Eur J Med Chem 2000;35(9):839-851
42. Shoblock JR. The pharmacology of Ro 64-6198, a systemically active, nonpeptide NOP receptor (opiate receptor-like 1, ORL-1) agonist with diverse preclinical therapeutic activity. CNS Drug Rev 2007;13(1):107-136
43. Schering Corp. High Affinity ligands for nociception receptor ORL1. US7485650; 2009
44. Kawamoto H, Ozaki S, Itoh Y, et al. Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)- 1-cyclooctylmethyl-3- hydroxymethyl- 4-piperidyl]-3-ethyl-1, 3-dihydro-2Hbenzimidazol- 2-one (J-113397). J Med Chem 1999;42(25):5061-5063
45. Chiou LC, Liao LL, Fan PC, et al. Nociceptin/ orphanin FQ receptors: pharmacology and clinical implications. Curr Drug Targets 2007;8:117-135
46. Satoh A, Sagara T, Sakoh H, et al. Identification of an orally active opioid receptor-like 1 (ORL1) receptor antagonist 4-{3-[(2R)- 2,3-dihydroxypropyl]-2-oxo-2,3-dihydro- 1H-benzimidazol-1-yl}-1-[(1S,3S,4R)- spiro[bicyclo[2.2.1]heptane-2,1¢-cyclopropan]- 3-ylmethyl]piperidine as clinical candidate. J Med Chem 2009;52(14):4091-4094
47. Goto Y, Arai-Otsuki S, Tachibana Y, et al. Identification of a novel spiropiperidine opioid receptor-like 1 antagonist class by a focused library approach featuring 3D-pharmacophore similarity. J Med Chem 2006;49(3):847-849
48. Fischetti C, Camarda V, Rizzi A, et al. Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist compound 24. Eur J Pharmacol 2009;614(1-3):50-57
49. Liao YY, Trapella C, Chiou LC. 1-benzyl-N-{3-[spiroisobenzofuran-1 (3H),4'-piperidin-1-yl]propyl}pyrrolidine- 2carboxamide (compound 24) antagonizes NOP receptormediated potassium channel activation in rat periaquaductal gray slices. Eur J Pharmacol 2009;606:84-89
50. Lambert DG. The nociceptin/ orphanin FQ receptor: a target with broad therapeutic potential. Nat Rev Drug Discov 2008;7(8):694-710
51. Shinkai H, Ito T, Iida T, et al. 4-Aminoquinolines: novel nociceptin antagonists with analgesic activity. J Med Chem 2000;43(24):4667-4677
52. Yamada H, Nakamoto H, Suzuki Y, et al. Pharmacological profiles of a novel opioid receptor-like1 (ORL(1)) receptor antagonist, JTC-801. Br J Pharmacol 2002;135(2):323-332
53. Zaveri N. Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents. Life Sci 2003;73(6):663-678
54. Japan Tobacco Co. Amide derivatives and nociception antagonists. US6410561B1; 2002
55. Japan Tobacco Co. Amide derivatives and nociception antagonists. US2006030565; 2006
56. Zaratin PF, Petrone G, Sbacchi M, et al. Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl- 7-[[4-(2,6-dichlorophenyl)piperidin-1-yl] methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten- 5-ol (SB-612111). J Pharmacol Exp Ther 2004;308(2):454-461
57. Spagnolo B, Carra G, Fantin M, et al. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl- 7-[[4-(2,6-dichlorophenyl)piperidin-1-yl] methyl]-6,7,8,9-tetrahydro-5H- benzocyclohepten- 5-ol]: in vitro studies. J Pharmacol Exp Ther 2007;321(3):961-967 (Pubitemid 46762706)
58. Trapella C, Guerrini R, Piccagli L, et al. Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist. Bioorg Med Chem 2006;14(3):692-704
59. Marti M, Trapella C, Morari M. The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA. J Neurochem 2008;107(6):1683-1696
60. Woodcock J, Witter J, Dionne RA. Stimulating the development of mechanism-based, individualized pain therapies. Nat Rev Drug Discov 2007;6(9):703-710
61. Purdue Pharma, L.P. Nociceptin anaglogs. US7563809; 2009
62. Gruenenthal GmbH. Substituted 4-aminocyclohexanols. US7183436; 2007
63. Gruenenthal GmbH. Spirocyclic cyclohexane compounds. US2005192333; 2005
64. Gruenenthal GmbH. Spirocyclic cyclohexan derivatives. EP2062898 A2; 2009
65. Gruenenthal GmbH. Use of morphine derivatives as medicaments for the treatment of neuropathic problems. US6476044 B1; 2002
66. Gruenenthal GmbH. Cyclohexylurea compounds. US2005261358A1; 2005
67. Nippon Shinyaku Co, Ltd. New physiologically active peptide. JP11021298; 1999
68. Okana M, Mori K, Nippon Shinyaku Co., Ltd. Hetero cycle derivatives and drugs. US2003119855A1; 2003
69. Okana M, Mori K, Nippon Shinyaku Co., Ltd. Quinazoline derivatives and drugs. US6794389B2; 2004
70. Nippon Shinyaku Co., Ltd. Peptide derivatives and medicinal compositions. US7163921B2; 2007
71. Stanford Research Institute. Agonist and antagonist ligands of the nociception receptor. WO2005060947A2; 2005
72. Khroyan TV, Zaveri NT, Polgar WE, et al. SR 16435 [1-(1-(bicyclo[3.3.1] nonan-9-yl)piperidin-4-yl)indolin-2-one], a novel mixed nociceptin/orphanin FQ/mu-opioid receptor partial agonist: analgesic and rewarding properties in mice. J Pharmacol Exp Ther 2007;320(2):934-943
73. Adapa ID, Toll L. Relationship between binding affinity and functional activity of nociceptin/orphanin FQ. Neuropeptides 1997;31(5):403-408
74. Zaveri N, Polgar WE, Olsen CM, et al. Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors. Eur J Pharmacol 2001;428(1):29-36
75. Wnendt S, Krïger T, Janocha E, et al. Agonistic effect of buprenorphine in a nociceptin/OFQ receptortriggered reporter gene assay. Mol Pharmacol 1999;56(2):334-338
76. Spagnolo B, Calo G, Polgar WE, et al. Activities of mixed NOP and mu-opioid receptor ligands. Br J Pharmacol 2008;153(3):609-619
77. Ciccocioppo R, Economidou D, Rimondini R, et al. Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system. Biol Psychiatry 2007;61(1):4-12
78. European Patent Office. Available from: http://ep.espacenet.com/
79. US Patent and Trademark Office. Available from: http://patft.uspto.gov/
80. World Intellectual Property Organization. Available from: http:// www.wipo.int/pctdb/en/index.jsp
81. Euro Celtique SA. Nociceptin analogs. US2009156640A1; 2009
82. Mono Biotech Lab AG. Use of a peptide as a therapeutic. WO2009046879A2; 2009
83. Pfizer. Treatment of Urinary conditions including incontinence. WO2005117862A1; 2005
84. Zealand Pharmaceuticals AS. Novel Peptide conjugates. US2003040472A1; 2003
85. Uni Degli Studi di Ferrara, Morari M, Marti M. NOP receptor agonists for the treatment of L-DOPA induced dyskinesia. WO2008062296A2; 2008
86. Bignan GC, Connelly PJ, Middleton SA. Recent advances towardthe discovery of ORL-1 agonists and antagonists. Expert Opin Ther Patents 2005;15(4):357-388
87. Heinricher MM. Nociceptin/orphanin FQ: pain, stress and neural circuits. Life Sci 2005;77(25):3127-3132
88. Zeilhofer HU, Calo G. Nociceptin/ orphanin FQ and its receptor-potential targets for pain therapy? J Pharmacol Exp Ther 2003;306(2):423-429
89. Suaudeau C, Florin S, Meunier JC, et al. Nociceptin-induced apparent hyperalgesia in mice as a result of the prevention of opioid autoanalgesic mechanisms triggered by the stress of an intracerebroventricular injection. Fundam Clin Pharmacol 1998;12(4):420-425
90. Rossi GC, Leventhal L, Pasternak GW. Naloxone sensitive orphanin FQ-induced analgesia in mice. Eur J Pharmacol 1996 311:R7-8
91. Heinricher MM, McGaraughty S, Grandy DK. Circuitry underlying antiopioid actions of orphanin FQ in the rostral ventromedial medulla. J Neurophysiol 1997;78(6):3351-3358
92. Pan Z, Hirakawa N, Fields HL. A cellular mechanism for the bidirectional pain-modulating actions of orphanin FQ/ nociceptin. Neuron 2000;26:515-522
93. Sakurada C, Sakurada S, Katsuyama S, et al. Involvement of tachykinin NK1 receptors in nociceptin-induced hyperalgesia in mice. Brain Res 1999;841(1-2):85-92
94. Obara I, Przewlocki R, Przewlocka B. Spinal and local peripheral antiallodynic activity of Ro64-6198 in neuropathic pain in the rat. Pain 2005;116(1-2):17-25
95. Varty GB, Hyde LA, Hodgson RA, et al. Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species. Psychopharmacology (Berl) 2005;182(1):132-143
96. Chiou LC, Fan SH, Chuang KC, et al. Pharmacological characterization of nociceptin/orphanin FQ receptors, a novel opioid receptor family, in the midbrain periaqueductal gray. Ann NY Acad Sci 2004;1025:398-403
97. Chiou LC, Chuang KC, Wichmann J, et al. Ro64-6198 [(1S,3aS)- 8-(2,3,3a,4,5,6-Hexahydro-1H-phenalen- 1-yl)-1-phenyl-1,3,8-triaza-spiro[4.5] decan-4-one] acts differently from nociceptin/orphanin FQ in rat periaquaductal gray slices. J Pharmacol Exp Ther 2004;311:645-651
98. Ko MC, Naughton NN, Traynor JR, et al. Orphanin FQ inhibits capsaicin-induced thermal nociception in monkeys by activation of peripheral ORL1 receptors. Br J Pharmacol 2002;135(4):943-950
99. Ko MC, Wei H, Woods JH, et al. Effects of intrathecally administered nociceptin/orphanin FQ in monkeys: behavioral and mass spectrometric studies. J Pharmacol Exp Ther 2006;318(3):1257-1264
100. Ko MC, Naughton NN. Antinociceptive effects of nociceptin/orphanin FQ administered intrathecally in monkeys. J Pain 2009;10(5):509-516
101. Ko MC, Woods JH, Fantegrossi WE, et al. Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys. Neuropsychopharmacology 2009;34(9):2088-2096
102. Hu E, Calo G, Guerrini R, et al. Longlasting antinociceptive spinal effects in primates of the novel nociceptin/ orphanin FQ receptor agonist UFP-112. Pain 2010;148:107-113
103. Ko MH, Kim YH, Woo RS, et al. NeuroReport 2002;13(13):1631-1633
104. Brooks H, Elton CD, Smart D, et al. Identification of nociceptin in human cerebrospinal fluid: comparison of levels in pain and non-pain states. Pain 1998;78(1):71-73
105. Anderberg UM, Liu Z, Berglund L, et al. Plasma levels on nociceptin in female fibromyalgia syndrome patients. Z Rheumatol 1998;57(Suppl 2):77-80
106. Barnes TA, Lambert DG. Editorial III: Nociceptin/orphanin FQ peptide-receptor system: are we any nearer the clinic? Br J Anaesth 2004;93(5):626-628
107. Raffaeli W, Samolsky Dekel BG, Landuzzi D, et al. Nociceptin levels in the cerebrospinal fluid of chronic pain patients with or without intrathecal administration of morphine. J Pain Symptom Manage 2006;32(4):372-377
108. Joseph T, Lee TL, Li C, et al. Levels of neuropeptides nocistatin, nociceptin/orphanin FQ and their precursor protein in a rat neuropathic pain model. Peptides 2007;28(7):1433-1440
109. Rizzi A, Bigoni R, Marzola G, et al. The nociceptin/orphanin FQ receptor antagonist, [Nphe1]NC(1-13)NH2, potentiates morphine analgesia. Neuroreport 2000; 11(11):2369-2372
110. Rizzi A, Nazzaro C, Marzola GG, et al. Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: pharmacological and genetic evidences. Pain 2006;124(1-2):100-108
111. Scoto GM, Arico G, Iemolo A, et al. Involvement of the nociceptin/orphanin FQ-NOP receptor system in the ventrolateral periaqueductal gray following mechanical allodynia in chronic pain. Life Sci 2009;85(5-6):206-210
112. Yu LC, Lu JT, Huang YH, et al. Involvement of endogenous opioid systems in nociceptin-induced spinal antinociception in rats. Brain Res 2002;945(1):88-96
113. Nazzaro C, Rizzi A, Salvadori S, et al. UFP-101 antagonizes the spinal antinociceptive effects of nociceptin/orphanin FQ: behavioral and electrophysiological studies in mice. Peptides 2007;28(3):663-669
114. Khroyan TV, Polgar WE, Orduna J, et al. Activity of new NOP receptor ligands in a rat peripheral mononeuropathy model: potentiation of morphine anti-allodynic activity by NOP receptor antagonists. Eur J Pharmacol 2009;610(1-3):49-54
115. Fu X, Wang YQ, Wu GC. Involvement of nociceptin/orphanin FQ and its receptor in electroacupunctureproduced anti-hyperalgesia in rats with peripheral inflammation. Brain Res 2006;1078:212-218
116. Tamai H, Sawamura S, Takeda K, et al. Anti-allodynic and anti-hyperalgesic effects of nociceptin receptor antagonist, JTC-801, in rats after spinal nerve injury and inflammation. Eur J Pharmacol 2005;510(3):223-228
117. Khroyan TV, Polgar WE, Jiang F, et al. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists. J Pharmacol Exp Ther 2009;331(3):946-953
118. Devine DP, Reinscheid RK, Monsma FJ Jr, et al. The novel neuropeptide orphanin FQ fails to produce conditioned place preference or aversion. Brain Res 1996;727(1-2):225-229
119. Murphy NP, Ly HT, Maidment NT. Intracerebroventricular orphanin FQ/nociceptin suppresses dopamine release in the nucleus accumbens of anaesthetized rats. Neuroscience 1996;75(1):1-4
120. Murphy NP, Lee Y, Maidment NT. Orphanin FQ/nociceptin blocks acquisition of morphine place preference. Brain Res 1999;832(1-2):168-170
121. Hao JX, Wiesenfeld-Hallin Z, Xu XJ. Lack of cross-tolerance between the antinociceptive effect of intrathecal orphanin FQ and morphine in the rat. Neurosci Lett 1997;223(1):49-52
122. Jhamandas KH, Sutak M, Henderson G. Antinociceptive and morphine modulatory actions of spinal orphanin FQ. Can J Physiol Pharmacol 1998;76(3):314-324
123. Abdulla FA, Smith PA. Axotomy reduces the effect of analgesic opioids yet increases the effect of nociceptin on dorsal root ganglion neurons. J Neurosci 1998;18(23):9685-9694
124. Kotlin̈ska J, Suder P, Legowska A, et al. Orphanin FQ/nociceptin inhibits morphine withdrawal. Life Sci 2000;66(8):PL119-23
125. Ciccocioppo R, Angeletti S, Panocka I, et al. Nociceptin/orphanin FQ and drugs of abuse. Peptides 2000;21(7):1071-1080
126. Toll LR, Khroyan TV, Polgar W, et al. Comparison of the anti-nociceptive and anti-rewarding profiles of novel bifunctional nociceptin/orphanin FQ receptor (NOPr)-mu opioid receptor (MOPr) ligands: implications for therapeutic applications. J Pharmacol Exp Ther 2009, published online 22 September 2009, doi:10.1124/ jpet.109.157446
127. Induru RR, Davis MP. Buprenorphine for neuropathic pain: targeting hyperalgesia. Am J Hosp Palliat Care 2009, published online 7 August 2009, doi:10.1177/1049909109341868
128. Chung S, Pohl S, Zeng J, et al. Endogenous orphanin FQ/nociceptin is involved in the development of morphine tolerance. J Pharmacol Exp Ther 2006;318(1):262-267
129. Sandrini M, Vitale G, Pini LA, et al. Nociceptin/orphanin FQ prevents the antinociceptive action of paracetamol on the rat hot plate test. Eur J Pharmacol 2005;507(1-3):43-48
130. D'Agostino B, Marrocco G, De Nardo M, et al. Activation of the nociceptin/orphanin FQ receptor reduces bronchoconstriction and microvascular leakage in a rabbit model of gastroesophageal reflux. Br J Pharmacol 2005;144(6):813-820
131. Oyama T, Sakana K. Antipruritics. US2008103162A1; 2008
132. Osi Pharmaceutical. (2-carboxamido) (3-amino)thiophene compounds. US7524859B2; 2009
133. Culpepper L. Generalized anxiety disorder and medical illness. J Clin Psychiatry 2009; 70:(Suppl 2):20-24
134. Roy-Byrne PP, Davidson KW, Kessler RC, et al. Anxiety disorders and comorbid medical illness. Gen Hosp Psychiatry 2008;30(3):208-225
135. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9(2):105-121
136. Goeldner C, Reiss D, Wichmann J, et al. Activation of nociceptin opioid peptide (NOP) receptor impairs contextual fear learning in mice through glutamatergic mechanisms. Neurobiol Learn Mem 2009;91(4):393-440
137. Vanderah TW, Raffa RB, Lashbrook J, et al. Orphanin-FQ/nociceptin: lack of anti nociceptive, hyperalgesic or allodynic effects in acute thermal or mechanical tests following intracerebroventricular or intrathecal administration to mice or rats. Eur J Pain 1998;2(3):267-278
138. Dietis N, Guerrini R, Calo G, et al. Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth 2009;103(1):38-49
139. Arduin M, Spagnolo B, Calo G, et al., Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with calpha,alpha-dialkylated amino acids. Bioorg Med Chem 2007;15(13):4434-4443
140. Kyle D, Goehring RR. Triazospiro compounds having nociceptin receptor affinity US2004132757A1; 2004